137 related articles for article (PubMed ID: 15357971)
1. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
[TBL] [Abstract][Full Text] [Related]
2. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.
Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Christ DD; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
Bioorg Med Chem Lett; 2003 Dec; 13(24):4299-304. PubMed ID: 14643313
[TBL] [Abstract][Full Text] [Related]
3. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
[TBL] [Abstract][Full Text] [Related]
4. Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.
Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Rao BG
Bioorg Med Chem Lett; 2008 Jan; 18(1):44-8. PubMed ID: 18054488
[TBL] [Abstract][Full Text] [Related]
5. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
[TBL] [Abstract][Full Text] [Related]
7. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.
Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
Bioorg Med Chem Lett; 2003 Dec; 13(24):4293-7. PubMed ID: 14643312
[TBL] [Abstract][Full Text] [Related]
8. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
[TBL] [Abstract][Full Text] [Related]
9. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
[TBL] [Abstract][Full Text] [Related]
12. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
[TBL] [Abstract][Full Text] [Related]
13. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
[TBL] [Abstract][Full Text] [Related]
14. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
16. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
[TBL] [Abstract][Full Text] [Related]
17. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
Kottirsch G; Koch G; Feifel R; Neumann U
J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.
Gilmore JL; King BW; Harris C; Maduskuie T; Mercer SE; Liu RQ; Covington MB; Qian M; Ribadeneria MD; Vaddi K; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2006 May; 16(10):2699-704. PubMed ID: 16516466
[TBL] [Abstract][Full Text] [Related]
19. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]